GR 2202
Alternative Names: GR-2202Latest Information Update: 14 Feb 2025
At a glance
- Originator Genrix (Shanghai) Biopharmaceuticals
- Class Anti-inflammatories; Bispecific antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases; Psoriasis
Most Recent Events
- 23 Jan 2025 Preclinical trials in Inflammatory bowel diseases in China (Parenteral) (Genrix (Shanghai) Biopharmaceuticals pipeline, January 2025)
- 23 Jan 2025 Preclinical trials in Psoriasis in China (Parenteral) (Genrix (Shanghai) Biopharmaceuticals pipeline, January 2025)